Acquisition method (AMC)
3
FSC 6505 × MELOXICAM TABLETS
MELOXICAM TABLETS
6505-01-541-3243 FSC 6505
NSN 6505-01-541-3243 (also written 6505015413243; NIIN 01-541-3243) is a meloxicam tablets in Federal Supply Class 6505, Drugs and Biologicals. 4 manufacturer part numbers from 4 suppliers are on record. It was last purchased in Oct 2026.
Open for bid
No open solicitations on record for this NSN right now.
Can you win it?
This item is coded to be bought directly from the actual manufacturer (AMC 3).
Suffix (AMSC)
Z
Competition
Coded for a named source
AMC 3: buy directly from the actual manufacturer, second or later time. AMSC Z: a commercial, nondevelopmental or off-the-shelf item. The codes describe the item's status on record, not any one solicitation. What the codes mean
What it is — can you make it?
Dimensions, the FLIS specification requirements, and the manufacturer part numbers already qualified against this NSN.
Specifications
From the federal catalog (DLA FLIS / PUB LOG) — what your part has to meet. Cited specification documents can be looked up in ASSIST Quick Search ↗, DoD's public spec repository — copy the document number in.
| Requirement | Value |
|---|---|
| PROTECTIVE STORAGE FEATURE AJCN | CONTROLLED ROOM TEMPERATURE |
| AMERICAN HOSPITAL FORMULARY SERVICE CLASSIFICATION NUMBER AJUC | 280804 |
| PART NAME ASSIGNED BY CONTROLLING AGENCY CXCY | MELOXICAM TABLETS 15MG BT 100S |
| SPECIAL FEATURES FEAT | 15MG; 100S |
Manufacturer part numbers
Commercial part numbers cross-referenced to this NSN in the federal catalog — the parts that have been accepted as satisfying this stock number, and who makes them.
| Part number | CAGE | Manufacturer |
|---|---|---|
| MOBIC | 55391 | BOEHRINGER INGELHEIM PHARMACEUTICALS INC |
| NDC68382-0051-01 | 6YA44 | ZYDUS PHARMACEUTICALS (USA) INC. |
| NDC72865-0138-01 | 86SL9 | XLCARE PHARMACEUTICALS INC |
| NDC76282-0153-01 | 6GFC4 | EXELAN PHARMACEUTICALS INC DIV EXELAN PHARMACEUTICALS |
What it pays — so you can quote
The government's own price and demand record for this NSN — what past awards cleared at, so you know where to land your quote.
Latest unit price
—
Purchases
0
Total spend
—
Oct 8, 2026
Last purchased
65 · 65.0/yr
Purchase records
$16,920
Total demand
$450.00
Latest award total
Purchase history
No priced purchases on record for this NSN yet.
Related contract actions
Contract action totals, not unit prices — obligation amounts from USAspending for related awards, shown for context only. These do not appear on the price chart above.
| Action date | Award # | Recipient | Agency | Obligation |
|---|---|---|---|---|
| Sep 16, 2026 | SPE2DX25D9900/SPE2DP26F000U ↗ | DMS PHARMACEUTICAL GROUP INC | — | $45.00 |
| Sep 16, 2026 | SPE2DX25D9900/SPE2DP26F000V ↗ | DMS PHARMACEUTICAL GROUP INC | — | $225.00 |
| Sep 16, 2026 | SPE2DX25D9900/SPE2DP26F000W ↗ | DMS PHARMACEUTICAL GROUP INC | — | $315.00 |
| Sep 16, 2026 | SPE2DX25D9900/SPE2DP26F000X ↗ | DMS PHARMACEUTICAL GROUP INC | — | $45.00 |
| Sep 16, 2026 | SPE2DX25D9900/SPE2DP26F000Y ↗ | DMS PHARMACEUTICAL GROUP INC | — | $450.00 |
| Sep 16, 2026 | SPE2DX25D9900/SPE2DP26F000Z ↗ | DMS PHARMACEUTICAL GROUP INC | — | $180.00 |
| Sep 16, 2026 | SPE2DX25D9900/SPE2DP26F001A ↗ | DMS PHARMACEUTICAL GROUP INC | — | $45.00 |
| Sep 16, 2026 | SPE2DX25D9900/SPE2DP26F001B ↗ | DMS PHARMACEUTICAL GROUP INC | — | $90.00 |
| Sep 16, 2026 | SPE2DX25D9900/SPE2DP26F001C ↗ | DMS PHARMACEUTICAL GROUP INC | — | $45.00 |
| Sep 16, 2026 | SPE2DX25D9900/SPE2DP26F001D ↗ | DMS PHARMACEUTICAL GROUP INC | — | $45.00 |
| Sep 16, 2026 | SPE2DX25D9900/SPE2DP26F001E ↗ | DMS PHARMACEUTICAL GROUP INC | — | $90.00 |
| Sep 16, 2026 | SPE2DX25D9900/SPE2DP26F001F ↗ | DMS PHARMACEUTICAL GROUP INC | — | $225.00 |
| Sep 16, 2026 | SPE2DX25D9900/SPE2DP26F001G ↗ | DMS PHARMACEUTICAL GROUP INC | — | $90.00 |
| Sep 16, 2026 | SPE2DX25D9900/SPE2DP26F001H ↗ | DMS PHARMACEUTICAL GROUP INC | — | $315.00 |
| Sep 16, 2026 | SPE2DX25D9900/SPE2DP26F001J ↗ | DMS PHARMACEUTICAL GROUP INC | — | $135.00 |
| Sep 16, 2026 | SPE2DX25D9900/SPE2DP26F001K ↗ | DMS PHARMACEUTICAL GROUP INC | — | $135.00 |
| Sep 16, 2026 | SPE2DX25D9900/SPE2DP26F001L ↗ | DMS PHARMACEUTICAL GROUP INC | — | $90.00 |
| Sep 16, 2026 | SPE2DX25D9900/SPE2DP26F001M ↗ | DMS PHARMACEUTICAL GROUP INC | — | $765.00 |
| Sep 16, 2026 | SPE2DX25D9900/SPE2DP26F001N ↗ | DMS PHARMACEUTICAL GROUP INC | — | $90.00 |
| Sep 16, 2026 | SPE2DX25D9900/SPE2DP26F001P ↗ | DMS PHARMACEUTICAL GROUP INC | — | $90.00 |
| Sep 16, 2026 | SPE2DX25D9900/SPE2DP26F001Q ↗ | DMS PHARMACEUTICAL GROUP INC | — | $315.00 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F001R ↗ | DMS PHARMACEUTICAL GROUP INC | — | $180.00 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F001S ↗ | DMS PHARMACEUTICAL GROUP INC | — | $1,350 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F001T ↗ | DMS PHARMACEUTICAL GROUP INC | — | $45.00 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F001U ↗ | DMS PHARMACEUTICAL GROUP INC | — | $90.00 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F001V ↗ | DMS PHARMACEUTICAL GROUP INC | — | $225.00 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F001W ↗ | DMS PHARMACEUTICAL GROUP INC | — | $225.00 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F001X ↗ | DMS PHARMACEUTICAL GROUP INC | — | $45.00 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F001Y ↗ | DMS PHARMACEUTICAL GROUP INC | — | $45.00 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F001Z ↗ | DMS PHARMACEUTICAL GROUP INC | — | $450.00 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F002A ↗ | DMS PHARMACEUTICAL GROUP INC | — | $225.00 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F002B ↗ | DMS PHARMACEUTICAL GROUP INC | — | $90.00 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F002C ↗ | DMS PHARMACEUTICAL GROUP INC | — | $315.00 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F002D ↗ | DMS PHARMACEUTICAL GROUP INC | — | $360.00 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F002E ↗ | DMS PHARMACEUTICAL GROUP INC | — | $45.00 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F002F ↗ | DMS PHARMACEUTICAL GROUP INC | — | $135.00 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F002G ↗ | DMS PHARMACEUTICAL GROUP INC | — | $45.00 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F002H ↗ | DMS PHARMACEUTICAL GROUP INC | — | $90.00 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F002J ↗ | DMS PHARMACEUTICAL GROUP INC | — | $45.00 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F002K ↗ | DMS PHARMACEUTICAL GROUP INC | — | $2,610 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F002L ↗ | DMS PHARMACEUTICAL GROUP INC | — | $2,250 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F002M ↗ | DMS PHARMACEUTICAL GROUP INC | — | $45.00 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F002N ↗ | DMS PHARMACEUTICAL GROUP INC | — | $135.00 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F002P ↗ | DMS PHARMACEUTICAL GROUP INC | — | $45.00 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F002Q ↗ | DMS PHARMACEUTICAL GROUP INC | — | $135.00 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F002R ↗ | DMS PHARMACEUTICAL GROUP INC | — | $450.00 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F002S ↗ | DMS PHARMACEUTICAL GROUP INC | — | $270.00 |
| Sep 17, 2026 | SPE2DX25D9900/SPE2DP26F002T ↗ | DMS PHARMACEUTICAL GROUP INC | — | $90.00 |
| Sep 20, 2026 | SPE2DX25D9900/SPE2DP26F003Y ↗ | DMS PHARMACEUTICAL GROUP INC | — | $270.00 |
| Sep 20, 2026 | SPE2DX25D9900/SPE2DP26F003Z ↗ | DMS PHARMACEUTICAL GROUP INC | — | $90.00 |
| Sep 21, 2026 | SPE2DX25D9900/SPE2DP26F004A ↗ | DMS PHARMACEUTICAL GROUP INC | — | $90.00 |
| Sep 23, 2026 | SPE2DX25D9900/SPE2DP26F007Q ↗ | DMS PHARMACEUTICAL GROUP INC | — | $90.00 |
| Sep 24, 2026 | SPE2DX25D9900/SPE2DP26F010N ↗ | DMS PHARMACEUTICAL GROUP INC | — | $45.00 |
| Sep 24, 2026 | SPE2DX25D9900/SPE2DP26F010Y ↗ | DMS PHARMACEUTICAL GROUP INC | — | $90.00 |
| Sep 24, 2026 | SPE2DX25D9900/SPE2DP26F011B ↗ | DMS PHARMACEUTICAL GROUP INC | — | $45.00 |
| Sep 24, 2026 | SPE2DX25D9900/SPE2DP26F013M ↗ | DMS PHARMACEUTICAL GROUP INC | — | $675.00 |
| Sep 25, 2026 | SPE2DX25D9900/SPE2DP26F015L ↗ | DMS PHARMACEUTICAL GROUP INC | — | $225.00 |
| Sep 25, 2026 | SPE2DX25D9900/SPE2DP26F015Z ↗ | DMS PHARMACEUTICAL GROUP INC | — | $45.00 |
| Sep 25, 2026 | SPE2DX25D9900/SPE2DP26F018Y ↗ | DMS PHARMACEUTICAL GROUP INC | — | $45.00 |
| Sep 28, 2026 | SPE2DX25D9900/SPE2DP26F019Q ↗ | DMS PHARMACEUTICAL GROUP INC | — | $45.00 |
| Sep 29, 2026 | SPE2DX25D9900/SPE2DP26F027W ↗ | DMS PHARMACEUTICAL GROUP INC | — | $180.00 |
| Sep 29, 2026 | SPE2DX25D9900/SPE2DP26F028Q ↗ | DMS PHARMACEUTICAL GROUP INC | — | $90.00 |
| Oct 1, 2026 | SPE2DX25D9900/SPE2DP27F0017 ↗ | DMS PHARMACEUTICAL GROUP INC | — | $540.00 |
| Oct 8, 2026 | SPE2DX25D9900/SPE2DP27F0182 ↗ | DMS PHARMACEUTICAL GROUP INC | — | $45.00 |
| Oct 8, 2026 | SPE2DX25D9900/SPE2DP27F0133 ↗ | DMS PHARMACEUTICAL GROUP INC | — | $450.00 |
Demand history
Every solicitation we've indexed for this NSN, open and closed — 2 on record. Closed RFQs (expired, cancelled, or awarded) stay here as a record of past demand; they never get removed.
Buying rhythm
How often does the government buy this item, and how long since the last time? Every solicitation and award on one line.
- Solicitation posted
- Award made
Dot size shows quantity. A faint bar joins a solicitation to the award made against it.
Who wins this item
Does one supplier win this every time, and are the winners on the listed-source list? One dot per award.
- Award in the last 2 years
- Older award
DMS PHARMACEUTICAL GROUP INC
last award Oct 2026
+53
Not listed BOEHRINGER INGELHEIM PHARMACEUTICALS INC
no award yet
no awards on record
Listed source EXELAN PHARMACEUTICALS INC DIV EXELAN PHARMACEUTICALS
no award yet
no awards on record
Listed source XLCARE PHARMACEUTICALS INC
no award yet
no awards on record
Listed source ZYDUS PHARMACEUTICALS (USA) INC.
no award yet
no awards on record
Listed source DMS PHARMACEUTICAL GROUP INC won 10 of the last 10 awards. DMS PHARMACEUTICAL GROUP INC won without being a listed source.
| Solicitation | Issued | Closes / closed | Qty | Status | |
|---|---|---|---|---|---|
| SPE2DP-26-T-4936 | Sep 9, 2026 | Sep 14, 2026 | 5 | Expired | View at DIBBS → |
| SPE2DP-26-T-1634 | Feb 5, 2026 | Feb 10, 2026 | 1 | Expired | View at DIBBS → |
Open RFQs on DIBBS → DIBBS award history ↗
About this data
- Unit prices: DLA DIBBS award records — every row links to its government record.
- AMSC: latest observed value from DIBBS solicitation history as of Oct 10, 2026.
- Contract action totals: USAspending, context only.
- Data last refreshed: 2026-10-10.
- Full methodology →
Cite this page
Citation
NSN Explorer. "MELOXICAM TABLETS." nsnexplorer.com, https://nsnexplorer.com/nsn/6505-01-541-3243/. Data as of October 19, 2026.
Link
https://nsnexplorer.com/nsn/6505-01-541-3243/